{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:50:33Z","timestamp":1781484633273,"version":"3.54.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,9,21]],"date-time":"2009-09-21T00:00:00Z","timestamp":1253491200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2009,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Interferon has been widely used in the treatment of genital warts for its immunomodulatory, antiproliferative and antiviral properties. Currently, no evidence that interferon improves the complete response rate or reduces the recurrence rate of genital warts has been generally provided. The aim of this review is to assess, from randomized control trials (RCTs), the efficacy and safety of interferon in curing genital warts.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We searched Cochrane Sexually Transmitted Diseases Group's Trials Register (January, 2009), Cochrane Central Register of Controlled Trials (2009, issue 1), PubMed (1950-2009), EMBASE (1974-2009), Chinese Biomedical Literature Database (CBM) (1975-2009), China National Knowledge Infrastructure (CNKI) (1979-2009), VIP database (1989-2009), as well as reference lists of relevant studies. Two reviewers independently screened searched studies, extracted data and evaluated their methodological qualities. RevMan 4.2.8 software was used for meta-analysis<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>12 RCTs involving 1445 people were included. Among them, 7 studies demonstrated the complete response rate of locally-used interferon as compared to placebo for treating genital warts. Based on meta-analysis, the rate of Complete response of the two interventions differed significantly (locally-used interferon:44.4%; placebo:16.1%). The difference between the two groups had statistical significance (RR 2.68, 95% CI 1.79 to 4.02, P &lt; 0.00001). 5 studies demonstrated the complete response rate of systemically-used interferon as compared to placebo for treating genital warts. Based on meta-analysis, the rate of Complete response of the two interventions had no perceivable discrepancy (systemically-used interferon:27.4%; placebo:26.4%). The difference between the two groups had no statistical significance (RR1.25, 95% CI 0.80 to 1.95, P &gt; 0.05). 7 studies demonstrated the recurrence rate of interferon as compared to placebo for treating genital warts. Based on meta-analysis, the recurrence rate of the two interventions had no perceivable discrepancy(interferon 21.1%; placebo: 34.2%). The difference between the two groups had no statistical significance (RR0.56, 95% CI 0.27 to 1.18, P &gt; 0.05). However, subgroup analysis showed that HPV-infected patients with locally administered interferon were less likely than those given placebo to relapse, but that no significant difference in relapse rates was observed between systemic and placebo. The reported adverse events of interferon were mostly mild and transient, which could be well tolerated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Interferon tends to be a fairly well-tolerated form of therapy. According to different routes of administration, locally-used interferon appears to be much more effective than both systemically-used interferon and placebo in either improving the complete response rate or reducing the recurrence rate for the treatment of genital warts.<\/jats:p><\/jats:sec>","DOI":"10.1186\/1471-2334-9-156","type":"journal-article","created":{"date-parts":[[2009,9,21]],"date-time":"2009-09-21T12:27:24Z","timestamp":1253536044000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Interferon for the treatment of genital warts: a systematic review"],"prefix":"10.1186","volume":"9","author":[{"given":"Jin","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-guo","family":"Pu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong-ming","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-jian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi-wen","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,9,21]]},"reference":[{"key":"921_CR1","first-page":"306","volume":"32","author":"Centers for Disease Control (CDC)","year":"1983","unstructured":"Centers for Disease Control (CDC): Condyloma acuminatum-United States, 1966-1981. MMWR. 1983, 32: 306-308.","journal-title":"MMWR"},{"key":"921_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0140-6736(83)90006-5","volume":"2","author":"PJ Baird","year":"1983","unstructured":"Baird PJ: Serological evidence for the association of papillomavirus and cervical neoplasia. Lancet. 1983, 2: 17-18. 10.1016\/S0140-6736(83)90006-5.","journal-title":"Lancet"},{"key":"921_CR3","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1056\/NEJM198404053101403","volume":"310","author":"CP Crum","year":"1984","unstructured":"Crum CP, Ikenberg H, Richart RM, Gissman L: Human papillomavirus type 16 and early cervical neoplasia. N Engl J Med. 1984, 310: 880-883.","journal-title":"N Engl J Med"},{"key":"921_CR4","doi-asserted-by":"crossref","first-page":"164","DOI":"10.5694\/j.1326-5377.1986.tb112256.x","volume":"144","author":"S Abraham","year":"1986","unstructured":"Abraham S: Human papilloma virus and cervical cancer. Med J Aust. 1986, 144: 164-","journal-title":"Med J Aust"},{"key":"921_CR5","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1093\/jnci\/85.12.958","volume":"85","author":"MH Sciffman","year":"1993","unstructured":"Sciffman MH, Bauer HM, Hoover RN, Glass AG, Cadell DM, Rush BB, Scott DR, Sherman ME, Kurman RJ, Wacholder S, Stanton CK, Manos MM: Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst. 1993, 85: 958-964. 10.1093\/jnci\/85.12.958.","journal-title":"J Natl Cancer Inst"},{"issue":"Suppl 2","key":"921_CR6","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/S1201-9712(07)60015-0","volume":"11","author":"J Paavonen","year":"2007","unstructured":"Paavonen J: Human papillomavirus infection and the development of cervical cancer and related genital neoplasias. Int J Infect Dis. 2007, 11 (Suppl 2): S3-9. 10.1016\/S1201-9712(07)60015-0.","journal-title":"Int J Infect Dis"},{"key":"921_CR7","first-page":"1","volume":"47","author":"JD Oriel","year":"1971","unstructured":"Oriel JD: Natural history of genital warts. Br J Vener Dis. 1971, 47: 1-13.","journal-title":"Br J Vener Dis"},{"key":"921_CR8","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/S0140-6736(86)90676-8","volume":"1","author":"HT Khawaja","year":"1986","unstructured":"Khawaja HT: Treatment of condyloma acuminatum. Lancet. 1986, 1: 208-209. 10.1016\/S0140-6736(86)90676-8.","journal-title":"Lancet"},{"key":"921_CR9","doi-asserted-by":"publisher","first-page":"239","DOI":"10.2165\/00128071-200506040-00004","volume":"6","author":"C O'Mahony","year":"2005","unstructured":"O'Mahony C: Genital warts: current and future management options. Am J Clin Dermatol. 2005, 6: 239-243. 10.2165\/00128071-200506040-00004.","journal-title":"Am J Clin Dermatol"},{"key":"921_CR10","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1086\/505982","volume":"43","author":"EF Dunne","year":"2006","unstructured":"Dunne EF, Markowitz LE: Genital human papillomavirus infection. Clin Infect Dis. 2006, 43: 624-629. 10.1086\/505982.","journal-title":"Clin Infect Dis"},{"key":"921_CR11","first-page":"801","volume":"7","author":"K Cook","year":"2008","unstructured":"Cook K, Brownell I: Treatments for genital warts. J Drugs Dermatol. 2008, 7: 801-807.","journal-title":"J Drugs Dermatol"},{"key":"921_CR12","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/BF02908284","volume":"5","author":"F Dianzani","year":"1975","unstructured":"Dianzani F: Viral interference and interferon. Ric Clin Lab. 1975, 5: 196-213.","journal-title":"Ric Clin Lab"},{"key":"921_CR13","doi-asserted-by":"publisher","first-page":"7914","DOI":"10.1073\/pnas.79.24.7914","volume":"79","author":"LP Turek","year":"1982","unstructured":"Turek LP, Byrne JC, Lowy DR, Dvoretzky I, Friedman RM, Howley PM: Interferon induces morphologic reversion with elimination of extrachromosomal viral genomes in bovine papillomavirus-transformed mouse cells. Proc Natl Acad Sci USA. 1982, 79: 7914-7918. 10.1073\/pnas.79.24.7914.","journal-title":"Proc Natl Acad Sci USA"},{"key":"921_CR14","first-page":"4948","volume":"42","author":"EC Borden","year":"1982","unstructured":"Borden EC, Hogan TF, Voelkel JG: Comparative antiproliferative activity in vitro of natural interferons alpha and beta for diploid and transformed human cells. Cancer Res. 1982, 42: 4948-4953.","journal-title":"Cancer Res"},{"key":"921_CR15","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3109\/00016348309155812","volume":"62","author":"N Einhorn","year":"1983","unstructured":"Einhorn N, Ling P, Strander H: Systemic interferon alpha treatment of human condylomata acuminata. Acta Obstet Gynecol Scand. 1983, 62: 285-287.","journal-title":"Acta Obstet Gynecol Scand"},{"key":"921_CR16","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/0002-9378(85)90103-6","volume":"153","author":"SA Gall","year":"1985","unstructured":"Gall SA, Hughes CE, Trofatter K: Interferon for the therapy of condyloma acuminatum. Am J Obstet Gynecol. 1985, 153: 157-163.","journal-title":"Am J Obstet Gynecol"},{"key":"921_CR17","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1. [http:\/\/www.cochrane-handbook.org]"},{"key":"921_CR18","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1093\/infdis\/158.5.934","volume":"158","author":"S Keay","year":"1988","unstructured":"Keay S, Teng N, Eisenberg M, Story B, Sellers PW, Merigan TC: Topical interferon for treating condyloma acuminata in women. J Infect Dis. 1988, 158: 934-939.","journal-title":"J Infect Dis"},{"key":"921_CR19","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1056\/NEJM198610233151704","volume":"315","author":"LJ Eron","year":"1986","unstructured":"Eron LJ, Judson F, Tucker S, Prawer S, Mills J, Murphy K, Hickey M, Rogers M, Flannigan S, Hien N, Katz HI, Goldman S, Gottlieb A, Adams K, Burton P, Tanner D, Taylor E, Peets E: Interferon therapy for condylomata acuminate. N Engl J Med. 1986, 315: 1059-1064.","journal-title":"N Engl J Med"},{"key":"921_CR20","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1001\/archderm.1986.01660150050014","volume":"122","author":"JC Vance","year":"1986","unstructured":"Vance JC, Bart BJ, Hansen RC, Reichman RC, McEwen C, Hatch KD, Berman B, Tanner DJ: Intralesional recombinant alpha-2 interferon for the treatment of patients with condyloma acuminatum or verruca plantaris. Arch Dermatol. 1986, 122: 272-277. 10.1001\/archderm.122.3.272.","journal-title":"Arch Dermatol"},{"key":"921_CR21","doi-asserted-by":"publisher","first-page":"675","DOI":"10.7326\/0003-4819-108-5-675","volume":"108","author":"RC Reichman","year":"1988","unstructured":"Reichman RC, Oakes D, Bonnez W, Greisberger C, Tyring S, Miller L, Whitley R, Carveth H, Weidner M, Krueger G, Yorkey L, Roberts NJ, Dolin R: Treatment of condyloma acumintaum with three different interferons administered intralensionally. A double-blind, placebo-controlled trial. Ann Intern Med. 1988, 108: 675-679.","journal-title":"Ann Intern Med"},{"key":"921_CR22","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/0002-9378(95)90404-2","volume":"172","author":"A Friedman-Kien","year":"1995","unstructured":"Friedman-Kien A: Management of condylomata acuminata with Alferon N injection, interferon alfa-n3(human leukocyte derived). AM J Obstet Gynecol. 1995, 172: 1359-1368. 10.1016\/0002-9378(95)90404-2.","journal-title":"AM J Obstet Gynecol"},{"key":"921_CR23","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1258\/0956462981921396","volume":"9","author":"TA Syed","year":"1998","unstructured":"Syed TA, Ahmadpour OA: Human leukocyte derived interferon-alpha in a hydrophilic gel for the treatment of intravaginal warts in women: a placebo-controlled, double-blind study. Int J STD AIDS. 1998, 9: 769-772. 10.1258\/0956462981921396.","journal-title":"Int J STD AIDS"},{"key":"921_CR24","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0090-8258(91)90009-T","volume":"43","author":"M Yliskoski","year":"1991","unstructured":"Yliskoski M, Syrj\u00e4nen K, Syrj\u00e4nen S, Saarikoski S, Nethersell A: Systemic alpha-interferon(Wellferon) treatment of genital human papillomavirus(HPV) type 6, 11, 16, and 18 infections: double-blind, placebo-controlled trial. Gynecol Oncol. 1991, 43: 55-60. 10.1016\/0090-8258(91)90009-T.","journal-title":"Gynecol Oncol"},{"key":"921_CR25","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1001\/jama.1991.03460200064036","volume":"265","author":"Condynomata international collaborative study group","year":"1991","unstructured":"Condynomata international collaborative study group: Recurrent condylomata acuminata treated with recombinant interferon alfa-2a. A multicenter double-blind placebo-controlled clinical trial. JAMA. 1991, 265: 2684-2687. 10.1001\/jama.265.20.2684.","journal-title":"JAMA"},{"key":"921_CR26","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2340\/0001555573223226","volume":"73","author":"Condynomata international collaborative study group","year":"1993","unstructured":"Condynomata international collaborative study group: Recurrent condylomata acuminata treated with recombinant interferon alpha-2a. A multicenter double-blind placebo-controlled clinical trial. Acta Derm Venereol. 1993, 73: 223-226.","journal-title":"Acta Derm Venereol"},{"key":"921_CR27","first-page":"198","volume":"21","author":"G Gentile","year":"1994","unstructured":"Gentile G, Formelli G, Busacchi P, Pelusi G: Systemic interferon therapy for female florid genital condylomata. Clin Exp Obstet Gynecol. 1994, 21: 198-202.","journal-title":"Clin Exp Obstet Gynecol"},{"key":"921_CR28","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1177\/095646249400500305","volume":"5","author":"L Olmos","year":"1994","unstructured":"Olmos L, Vilata J, Rodr\u00edguez Pichardo A, Lloret A, Ojeda A, Calder\u00f3n MD: Double-blind, randomized, clinical trial on the effect of interferon-beta in the treatment of condylomata acuminata. Int J STD AIDS. 1994, 5: 182-185.","journal-title":"Int J STD AIDS"},{"key":"921_CR29","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/j.1468-3083.1994.tb00361.x","volume":"3","author":"J Handley","year":"1994","unstructured":"Handley J, Dinsmore W: Treatment of anogenital warts. Eur Acad Dermatol Venereol. 1994, 3: 251-256. 10.1111\/j.1468-3083.1994.tb00361.x.","journal-title":"Eur Acad Dermatol Venereol"},{"key":"921_CR30","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1016\/0002-9378(95)90399-2","volume":"172","author":"A Ferenczy","year":"1995","unstructured":"Ferenczy A: Epidemiology and clinical pathophysiology of condylomata acuminata. Am J Obstet Gynecol. 1995, 172: 1331-1339. 10.1016\/0002-9378(95)90399-2.","journal-title":"Am J Obstet Gynecol"},{"key":"921_CR31","first-page":"393","volume":"74","author":"P Benedetti Panici","year":"1989","unstructured":"Benedetti Panici P, Scambia G, Baiocchi G, Perrone L, Pintus C, Mancuso S: Randomized clinical trial comparing systemic interferon with diathermocoagulation in primary multiple and widespread anogenital condyloma. Obstet Gynecol. 1989, 74: 393-397.","journal-title":"Obstet Gynecol"},{"key":"921_CR32","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0022-5347(17)37326-3","volume":"147","author":"BE Davis","year":"1992","unstructured":"Davis BE, Noble MJ: Initial experience with combined interferon-alpha 2B and carbon dioxide laser for the treatment of condyloma acuminata. J Urol. 1992, 147: 627-629.","journal-title":"J Urol"},{"key":"921_CR33","first-page":"598","volume":"11","author":"G Von Krogh","year":"2001","unstructured":"Von Krogh G: Management of anogenital warts(condylomata acuminate). Eur J Dermatol. 2001, 11: 598-603.","journal-title":"Eur J Dermatol"},{"key":"921_CR34","first-page":"120","volume":"19","author":"L Resta","year":"1992","unstructured":"Resta L, Troia M, Russo S, Colucci GA, Sabatini R, Loiudice L, Cagnazzo G: Variations of lymphocyte sub-populations in vulvar condylomata during therapy with beta-interferon. Clin Exp Obstet Gynecol. 1992, 19: 120-124.","journal-title":"Clin Exp Obstet Gynecol"},{"key":"921_CR35","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","volume":"273","author":"KF Schulz","year":"1995","unstructured":"Schulz KF, Chalmers I, Hayes RJ, Altman DG: Empirical evidence of bias: Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995, 273: 408-412. 10.1001\/jama.273.5.408.","journal-title":"JAMA"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-9-156.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2334-9-156\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-9-156","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-9-156.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T17:29:55Z","timestamp":1710610195000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/1471-2334-9-156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,21]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["921"],"URL":"https:\/\/doi.org\/10.1186\/1471-2334-9-156","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,21]]},"assertion":[{"value":"12 March 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2009","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2009","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"156"}}